miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
• Dysregulated miRNAs are implicated in prostate cancer diagnosis and determining disease aggressiveness.
• miR-9's role as an oncomiR has been established in various cancers but not definitively in prostate cancer.

Purpose of the Study:

• To identify and validate microRNAs (miRNAs) involved in prostate cancer progression.
• To investigate the specific role of miR-9 as an oncomiR in prostate cancer.
• To explore the therapeutic potential of targeting miR-9 in prostate cancer.

Main Methods:

• miRNA panel RT-qPCR and high-throughput sequencing to identify dysregulated miRNAs.
• Analysis of prostate cancer cell lines (P69, M12, DU-145, PC3) and patient tumor tissues.
• In vivo studies using male athymic nude mice to assess tumor growth and metastasis.
• Bioinformatic analysis to identify miR-9 targets (e-cadherin, SOCS5).

Main Results:

• miR-9 was consistently upregulated in prostate cancer cell lines and tumor tissues compared to normal tissues.
• Inhibition of miR-9 significantly reduced the migratory and invasive potential of prostate cancer cells.
• Targeting miR-9 led to reduced tumor growth and metastasis in vivo.
• miR-9 was confirmed to target e-cadherin and SOCS5, influencing their protein expression.

Conclusions:

• miR-9 functions as an oncomiR in prostate cancer, promoting cell migration, invasion, and metastasis.
• miR-9 represents a potential diagnostic biomarker and therapeutic target for aggressive prostate cancer.
• Targeting miR-9 offers a promising strategy to inhibit prostate cancer progression and metastasis.